Safety Signals of Daratumumab + KRd: Real-World Translation
Panelists discuss how daratumumab plus KRd demonstrates manageable toxicity and strong real-world feasibility with appropriate supportive care.
EP: 1.Review of Latest Guidelines on Quad Therapy in NDMM
EP: 2.Classifying High-Risk Patients With NDMM
EP: 3.Pretesting Prior to Quad Therapy for NDMM
EP: 4.Overview of the ADVANCE Study: Methodology and Design
EP: 5.Expert Perspectives on the Design of the ADVANCE Trial
EP: 6.Key Efficacy Results From ADVANCE: MRD Negativity Stratified by Age and Risk
EP: 7.Transplant Eligible vs Ineligible: Clinical Implications
EP: 8.Safety Signals of Daratumumab + KRd: Real-World Translation
Panelists discuss how safety findings from ADVANCE align with prior daratumumab experience, confirming manageable toxicity profiles when administered with carfilzomib, lenalidomide, and dexamethasone (KRd). They highlight key adverse events—hematologic suppression, infusion reactions, and infection risk—while noting low discontinuation rates. Supportive measures such as antiviral prophylaxis, intravenous immunoglobulin supplementation, and careful monitoring help mitigate risks. They stress that real-world success depends on early recognition and multidisciplinary coordination to manage adverse effects without compromising efficacy.
